November 3, 2025
1 min read

Alvotech plant issues foil another FDA review, this time for Teva-partnered Simponi biosimilar

Patients hoping to get their hands on a cheaper copycat of Johnson & Johnson’s fading anti-inflammatory blockbuster Simponi may have to wait for a few months more, thanks to an FDA inspection this summer that has derailed a leading biosimilar application from partners Teva and Alvotech.

Leave a Reply

Your email address will not be published.

Previous Story

Ductal vs. lobular breast cancer: Symptoms, treatments, and more

Next Story

Trump administration says SNAP will be partially funded in November

Previous Story

Ductal vs. lobular breast cancer: Symptoms, treatments, and more

Next Story

Trump administration says SNAP will be partially funded in November

Latest from Blog

ROFI Drives New Approach to Crop Nutrition

With input costs continuing to pressure farm budgets, some growers are making difficult decisions to reduce fertilizer application rates. While that strategy may ease upfront expenses, it is also accelerating a broader
Go toTop